Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.

Scientific publication - Journal Article uoadl:2951208 24 Read counter

Description
Contents

Unit:

Faculty of Medicine

Title:

Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.

Languages of Item:

English

Abstract:

Empty abstract

Publication year:

2009

Authors:

Terpos, Evangelos
Christoulas, Dimitrios
Migkou, Magdalini
Gavriatopoulou, Maria
Papatheodorou, Athanasios
Eleutherakis-Papaiakovou, Evangelos
Manios, Efstathios
Kastritis, Efstathios
Papadimitriou, Christos
Dimopoulos, Meletios A

Journal:

Blood Disease Weekly

Publisher:

Content Repository Only!

Volume:

114

Number:

Pages:

3863

Main subject category:

Health Sciences

Persistent URL:

https://pergamos.lib.uoa.gr/uoa/dl/object/2951208

Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.

The digital material of the item is not available.